secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001213900-22-072556
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharma Q3 net loss narrows to $3.1M; CEO promoted, AD04 regulatory submission in progress
--------------------------------------------------------------------------------

- Net loss of $3.1M ($0.12/shr) vs $4.3M ($0.22/shr) in Q3 2021.
- Cash and equivalents $5.8M as of Sep 30, 2022, from $6.1M at Dec 31, 2021.
- R&D expenses fell 26% to $1.3M; G&A expenses fell 18% to $1.9M vs year-ago quarter.
- Cary Claiborne promoted to President and CEO; William Stilley named CEO of Purnovate subsidiary.
- Advancing AD04 ONWARD Phase 3 results to regulators; active partnership discussions for AD04 and Purnovate compounds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/0001213900-22-072556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/ea168662-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-072556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer